The relevance of the crosstalk between IL7R and MYC activation in the genesis of T-ALL suggests that therapeutic combinations involving bromodomain inhibitors, which can downregulate both MYC and IL7R [64], may benefit T-ALL cases with IL7R mutation and especially those with refractory or relapsed disease [65]. This evidence concerns the gene IL7R and acute lymphoblastic leukemia.